Swiss pharma giants fined by France in ongoing eye drug clash
The two drugs are used to to treat patients with blindness-causing macular degeneration.
Keystone/Jay
The pharmaceutical companies Novartis and Roche have been fined €444 million (CHF481 million) by the French competition authority for applying abusive practices to push costly eye injection Lucentis over a cheaper drug.
This content was published on
2 minutes
swissinfo.ch with Reuters/ug
Português
pt
França processa farmacêuticas suíças por injeção de colírio
The two Swiss pharma companies abused their dominant position to push Lucentis at the expense of the drug Avastin, the French competition watchdog announced on Wednesday.
It added that Novartis was also punished for “unjustifiably exaggerating” Avastin’s risks.
Novartis, which said it would appeal, is facing high stakes in protecting Lucentis sales in Europe, after the uptake of its newest eye drug, Beovu, has been slowed by safety concerns.
Novartis must pay €385 million and Roche about €60 million, according to the decision.
Roche and Novartis are partners on Lucentis, with Roche selling it in the United States and Novartis selling it in Europe.
Running battle
The fines are the latest development in a running battle between the drug makers and countries where some doctors have turned to Roche’s cheaper Avastin to replace costly Lucentis, to treat patients with blindness-causing macular degeneration (AMD).
Lucentis was developed for AMD but works like cancer drug Avastin by inhibiting blood vessel growth. Avastin is used “off-labelExternal link” to treat AMD.
The French authority said Lucentis, injected roughly once per month, costs €1,161 per injection, while Avastin runs at €30 to €40 per shot.
Similar disputes have emerged elsewhere. In 2018, Novartis and Roche lost a bid in Britain to block doctors from making Avastin the preferred option for AMD.
RocheExternal link said it was disappointed and would “assess” the situation.
NovartisExternal link said a French rule allowing off-label use of medicines in diseases with approved treatments threatens the system of ensuring safe and effective drugs.
“This decision relies on a gross misinterpretation of the facts and a distortion of previous case law,” Novartis said.
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
Nearly one in two bicycles sold in Switzerland is an e-bike
This content was published on
In 2024, almost every second bicycle sold in Switzerland was an e-bike. Overall, around 14% fewer bikes were sold than in the previous year.
Over 200 Swiss firms sign up to CO2 reduction targets
This content was published on
To date, 237 companies from Switzerland have joined the Science Based Targets Initiative (SBTi), committing to CO2 reduction targets in line with the Paris Accord.
Geneva-based UN migration office cuts fifth of workforce
This content was published on
The UN's International Organisation for Migration HQ in Geneva is slashing 20% of its 1,000 staff due to the US aid freeze.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche clears drug that caused vision loss in India
This content was published on
“In India, Roche has completed an assessment of the available information on the batch reported to have been used at C.H Nagri Eye Hospital in Ahmedabad, Gujarat. We can confirm that based on the information available, there is no reason to believe there were quality problems with the Avastin (Bevacizumab) vials in this batch,” a…
Novartis pays big fine for bribing doctors in the US
This content was published on
Swiss pharma company Novartis will pay $729 million to US authorities in an out-of-court settlement over charges that the company bribed doctors to use its drugs.
Can big pharma’s money solve the antibiotics crisis?
This content was published on
Big pharmaceutical companies are investing nearly $1 billion in a fund to bring new antibiotics to patients. What's the catch?
Are Big Pharma’s big innovation plans what we need?
This content was published on
Our analysis of what the biggest global companies in Switzerland are up to. This week: Big Pharma's R&D plans, coronavirus impact, and #cryptoleaks.
Big companies get ready for a contentious political season
This content was published on
Our analysis of what the biggest global companies in Switzerland are up to. This week: companies mixed up in politics and foreign aid.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.